Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib
The present case demonstrates the potential of bortezomib as a treatment option for refractory AIHA cases, particularly in children. <b>Trial Registration</b>: The authors have confirmed clinical trial registration is not needed for this submission.
Authors
- Taco W. Kuijpers (ORCID: https://orcid.org/0000-0002-7421-3370)
- Boukje M. Beuger
- Josephine M. I. Vos (ORCID: https://orcid.org/0000-0003-3229-9556)
- Hanke L. Matlung
- Robin van Bruggen (ORCID: https://orcid.org/0000-0002-1676-0720)
- Eva Rettenbacher
- Silvia Neri (ORCID: https://orcid.org/0009-0002-6634-5127)
- Corien L. Eckhardt (ORCID: https://orcid.org/0009-0007-0025-6961)
- Folman Folman
Institutions
- Amsterdam UMC Location University of Amsterdam (NL)
- Sanquin (NL)
- Emma Kinderziekenhuis (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Amsterdam University of Applied Sciences (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- eJHaem
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1002/jha2.70162
- Primary Topic
- Blood groups and transfusion
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission